Information updates

Evusheld for COVID-19 prophylaxis

The National (Australian) COVID-19 Clinical Evidence Taskforce (the Taskforce), has issued recommendations on the use of monoclonal antibodies tixagevimab plus cilgavimab (Evusheld), for COVID-19 prevention (prophylaxis). Evusheld is supplied by Astra Zeneca and has provisional approval in Australia from the Therapeutic Goods Administration (TGA) since January 2022:

Product information is available at which includes the following details:

  • Evusheld is administered by intramuscular (IM) injection, and should be given with caution to patients with thrombocytopenia or any coagulation disorder.
  • Serious adverse events are rare, as listed in table 5.
  • Efficacy and safety of Evusheld in children (less than 18 years) has not been established.
  • Evusheld is not recommended as a substitute for vaccination.
  • The trial of Evusheld included particpants who had moderate to severe immune compromise due to a medical condition or immunosuppressive medications/treatments, that made it likely that they will not mount an adequate immune response to COVID‐19 vaccination.

Supply of Evusheld is currently limited, and is only available in Australia from the National Stockpile. Therefore Evusheld can only be considered for pre-exposure prophylaxis in exceptional circumstances, in people who are severely immunocompromised and at high risk of progression to severe COVID-19. This includes people who are expected to have an inadequate response to vaccination, who have:

  • Solid organ transplant, blood or bone marrow transplant.
  • Primary immune deficiencies, also known as inborn errors of immunity.
  • Secondary immune deficiencies, including patients on significant immunosuppressive medications and some people with HIV.

ASCIA recommends that allocation of Evusheld should be based on the severity of the underlying immune deficiency, the risk of acquiring coronavirus infection, and the risk of severe COVID, supported by the patient’s specialist recommendation.

It is noted that there is currently no clinical data regarding effectiveness of Evusheld specific to SARS-CoV-2 variants of concern. 

The Taskforce recommendations on Evusheld for prophylaxis are available at: 

This information is also available at


This news item was issued on 28 March 2022 and updated on 6 May 2022 by Jill Smith, CEO of the Australasian Society of Clinical Immunology and Allergy (ASCIA), the peak professional body for clinical immunology and allergy in Australia and New Zealand.   

Mod ASCIA Member
Donate to AIFA
go to NAC website

ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links


ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.

Information Partner

Official Information Partner of Healthdirect Australia